Jan Homann, Tim Osburg, Olena Ohlei, Valerija Dobricic, Laura Deecke, Isabelle Bos, Rik Vandenberghe, Silvy Gabel, Philip Scheltens, Charlotte E Teunissen, Sebastiaan Engelborghs, Giovanni Frisoni, Olivier Blin, Jill C Richardson, Regis Bordet, Alberto Lleó, Daniel Alcolea, Julius Popp, Christopher Clark, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Richard J B Dobson, Cristina Legido-Quigley, Kristel Sleegers, Christine Van Broeckhoven, Michael Wittig, Andre Franke, Christina M Lill, Kaj Blennow, Henrik Zetterberg, Simon Lovestone, Johannes Streffer, Mara Ten Kate, Stephanie J B Vos, Frederik Barkhof, Pieter Jelle Visser, Lars Bertram
Alzheimer's disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, aging populations. AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade. Most of these GWAS used dichotomized clinical diagnostic status, i.e., case vs. control classification, as outcome phenotypes, without the use of biomarkers. An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work...
2022: Frontiers in Aging Neuroscience